GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients" is generating significant coverage in the Business category, with 1 articles from 1 distinct sources tracked by PULSE so far.
Outlets currently covering the story include KTLA. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 2h ago.
Quick answers
Why is "GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients" trending?
Because 1 independent news sources published 1 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (2)
- Patients sue GLP-1 makers over sudden loss of vision The Hill · 20h ago
- Patients sue GLP-1 makers over sudden loss of vision KTLA · 20h ago
Topics
Related trends
Novo defends diversification push as CEO eyes deals beyond obesity
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial
Roche's experimental GLP-1/GIP drug enicepatide delivers positive phase II results, cutting body weight and blood-sugar levels.
What GLP-1 users should know about the potential risk of a rare type of vision loss
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Novo Nordisk shares plunge over 7% as new targets fail to reassure investors
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
‘Boom, lights out’: Massachusetts man shares sudden blindness journey after taking GLP-1
Patients file lawsuits against GLP-1 drugmakers following rare cases of sudden vision loss and blindness.
Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.